---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059297"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T03:16:20.491049+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Armata Q1 loss widens to $11.3M; positive Ph1b/2a data for AP-PA02; closes $30M convertible

## Summary
- Positive topline data from AP-PA02 Ph1b/2a in cystic fibrosis; first patient dosed in Phase 2 NCFB study.
- AP-SA02 advanced: second cohort dosed in Staphylococcus aureus bacteremia Ph1b/2a; PJI study start-up activities.
- Closed $30M secured convertible credit agreement with Innoviva (largest shareholder) to fund trials and manufacturing.
- Q1 loss from operations $(11.3)M vs $(8.8)M a year ago; cash $25.1M vs $14.9M at Dec 31, 2022.
- Grant revenue $0.8M from MTEC/DoD; $16.3M total grant funding expected for AP-SA02 program.

## SEC filing metadata
- accession: 0001104659-23-059297
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/0001104659-23-059297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/tm2315601d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059297
- JSON: https://secwatch.observer/filing/0001104659-23-059297.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059297.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023, in the press release furnished hereto as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/0001104659-23-059297-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.